Reprint

Molecular Psychiatry

Edited by
July 2020
388 pages
  • ISBN978-3-03936-120-5 (Hardback)
  • ISBN978-3-03936-121-2 (PDF)

This is a Reprint of the Special Issue Molecular Psychiatry that was published in

Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology
Summary

The book highlights important aspects of Molecular Psychiatry, including molecular mechanisms, animal models, biomarkers, advanced methods, drugs and antidepressant response, as well as genetics and epigenetics. Molecular mechanisms are a vital part of the search for the biological basis of psychiatric disorders, providing molecular hints that can later be tested as biomarkers or targets for drug development. Animal models represent a commonly used approach to aid in this bench-to-bed translation; the examples here are social defeat stress and the Roman High-Avoidance (RHA) and the Roman Low-Avoidance (RLA) rats. For biomarkers, psychiatric disorders pose a particular challenge due to the tissue specificity of many currently investigated biomarkers; i.e., not all blood-based measures directly represent changes in the brain. The Ebook includes five articles focused on the challenges of identifying clinically and biologically relevant biomarkers for psychiatric disorders.

Scientific progress typically is fostered by the development of new methods. The application of machine learning methods for the proper analysis of Big Data and induced pluripotent stem cells are examples outlined in this Ebook. Furthermore, three articles are devoted to the understanding of the mechanisms of actions of existing drugs with the ultimate goal of identifying ways to predict treatment response in patients. Finally, three articles deepen the insight into the genetics and epigenetics of psychiatric disorders.

Format
  • Hardback
License and Copyright
© 2020 by the authors; CC BY-NC-ND license
Keywords
cardiovascular disease; cell adhesion molecules; immunology; inflammation; nervous system; schizophrenia; bipolar disorder; major depressive disorder; DNA methylation; response variability; antipsychotics; drug design; multi-target drugs; polypharmacology; schizophrenia; multi-task learning; machine learning; biomarker discovery; psychiatry; serotonin; 5-HT 4 receptor; 5-HT4R; depression; mood disorder; expression; Alzheimer’s disease; cognition; Parkinson’s disease; forced swimming; Roman rat lines; depression; stress; hippocampus; BDNF; trkB; PSA-NCAM; western blot; immunohistochemistry; schizophrenia; general cognitive function; intelligence; GWAS; genetic correlation; childhood-onset schizophrenia (COS); induced pluripotent stem cell (iPSC); copy number variation (CNV); early neurodevelopment; neuronal differentiation; synapse; dendritic arborization; miRNAs; stress physiology; cytoskeleton; actin dynamics; DRR1; TU3A; FAM107A; acid sphingomyelinase; alcohol dependence; liver enzymes; sphingolipid metabolism; withdrawal; Hsp90; GR; stress response; steroid hormones; molecular chaperones; psychiatric disease; circadian rhythms; FKBP51; FKBP52; CyP40; PP5; DISC1; neurodevelopment; synapse; CRMP-2; proteomics; depression; antidepressant treatment; HPA axis; gene expression; FKBP5; FKBP51; depression; sleep; sleep EEG; biomarkers; antidepressants; cordance; gender; sex difference; depression; antidepressant; rapid-acting; antidepressant; Ketamine; endocrinology; (2R,6R)-Hydroxynorketamine; electroconvulsive therapy; basic-helix-loop-helix; brain; coactivator; glucocorticoids; hippocampus; mineralocorticoid receptor knockout; stress; transcription biology; dopaminergic gene polymorphisms; affective temperament; obesity; alpha-synuclein; SNCA; major depression; Hamilton Scale of Depression; major depressive disorder; chemokines; neuroinflammation; social defeat; Immune response; T cells; susceptibility; resilience; major depression; Treg cells; Th17 cells; behavior; PPARγ; n/a